Athena - Heart [310]

Clinicians should monitor several factors to prevent adverse outcomes:

The official FDA label outlines critical safety measures based on ATHENA data: : ATHENA HEART [310]

: Contraindicated in patients with symptomatic heart failure or recent hospitalization for heart failure (NYHA Class IV or symptomatic Class II-III). Clinicians should monitor several factors to prevent adverse

: Conduct regular ECGs to monitor for potential proarrhythmic effects or excessive QT prolongation. ATHENA HEART [310]

The ATHENA trial was a landmark study that evaluated the efficacy of dronedarone in reducing cardiovascular hospitalizations or death.